Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AbCellera Biologics Q2 EPS $(0.12) Beats $(0.15) Estimate, Sales $17.084M Beat $5.824M Estimate

Author: Benzinga Newsdesk | August 07, 2025 03:33pm
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 21.05 percent. This is a 7.69 percent increase over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $17.084 million which beat the analyst consensus estimate of $5.824 million by 193.31 percent. This is a 133.29 percent increase over sales of $7.323 million the same period last year.

Posted In: ABCL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist